

(19) **DANMARK**

(10) **DK/EP 2294225 T3**



(12)

Oversættelse af  
europæisk patentskrift

Patent- og  
Varemærkestyrelsen

- 
- (51) Int.Cl.: **C 12 Q 1/68 (2006.01)**
- (45) Oversættelsen bekendtgjort den: **2015-03-30**
- (80) Dato for Den Europæiske Patentmyndigheds bekendtgørelse om meddelelse af patentet: **2014-12-17**
- (86) Europæisk ansøgning nr.: **09774388.4**
- (86) Europæisk indleveringsdag: **2009-06-30**
- (87) Den europæiske ansøgnings publiceringsdag: **2011-03-16**
- (86) International ansøgning nr.: **US2009049323**
- (87) Internationalt publikationsnr.: **WO2010002938**
- (30) Prioritet: **2008-06-30 US 77113 P**
- (84) Designerede stater: **AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR**
- (73) Patenthaver: **Life Technologies Corporation, 5791 Van Allen Way, Carlsbad, CA 92008, USA**
- (72) Opfinder: **WANG, Dennis, Y., 8888 Bellina Commons, Dublin, CA 94568, USA**  
**HENNESSY, Lori, K., 687 29th Avenue, San Mateo, CA 94403, USA**  
**CHANG, Chien-wei, 2170 Carlmont Drive Apt. 2, Belmont, CA 94002, USA**
- (74) Fuldmægtig i Danmark: **Chas. Hude A/S, H.C. Andersens Boulevard 33, 1780 København V, Danmark**
- (54) Benævnelse: **Fremgangsmåde til direkte amplificering fra rå nucleinsyreprøver**
- (56) Fremdragne publikationer:  
**EP-B1- 1 050 587**  
**WO-A1-2006/090987**  
**WO-A2-00/50564**  
**WO-A2-2008/002740**  
**US-A- 5 837 453**  
**US-A1- 2002 012 924**  
**US-A1- 2005 026 147**  
**US-A1- 2008 124 768**  
**US-A1- 2008 138 804**  
**US-B1- 6 297 005**  
**NAGAI M ET AL: "ADDITIVE EFFECTS OF BOVINE SERUM ALBUMIN, DITHIOTHREITOL, AND GLYCEROL ON PCR", BIOCHEMISTRY AND MOLECULAR BIOLOGY INTERNATIONAL, ACADEMIC PRESS, LONDON, GB, vol. 44, no. 1, 1 January 1998 (1998-01-01), pages 157-163, XP009023284, ISSN: 1039-9712**  
**ABU AL-SOUD WALEED ET AL: "Effects of amplification facilitators on diagnostic PCR in the presence of blood, feces, and meat", JOURNAL OF CLINICAL MICROBIOLOGY, vol. 38, no. 12, December 2001 (2001-12), pages 4463-4470, ISSN: 0095-1137**

Fortsættes ...



**Description****Cross Reference to Related Applications**

[0001] This application claims priority benefit under 35 U.S. C. § 119(e) from  
5 U.S. Application No. 61/077,113 filed June 30, 2008.

**Field**

[0002] The present teachings generally relate to methods of directly amplifying  
nucleic acids from crude samples.

10 **Introduction**

[0003] Rapid and accurate detection of DNA profiles is a key aspect of forensic  
casework sample analysis. Crude samples such as blood and buccal swabs  
contain substances that can inhibit the activity of the polymerases used for  
15 PCR-based short tandem repeat (STR) typing. Historically, it has been neces-  
sary to remove inhibitors and purify DNA before performing downstream enzy-  
matic manipulations such as PCR amplification. Many kinds of DNA isolation  
and purification methods and kits are commercially available. WO 00/50564 A2  
relates to a composition and to a method for extracting DNA. WO 2008/002740  
20 A2 provides methods and compositions for extracting RNA from cells. WO  
2006/090987 A1 describes methods for performing a direct enzymatic reaction  
involving a nucleic acid molecule, and uses a zwitterionic buffer and/or a non-  
reducing carbohydrate to prevent the biological specimen from inhibiting the en-  
zymatic reaction. EP 1 050 587 B1 describes compositions and methods for the  
25 generation of nucleic acids from a ribonucleic acid template and further nucleic  
acid replication. However, their use adds time and expense to the preparation of  
samples for subsequent analysis.

**Summary**

30 [0004] The invention can be defined by the appending claims. According to a

first aspect, the invention provides a method according to claims 1-5, 7 and 9. According to a second aspect, the invention provides a reaction mixture according to claims 6 and 8. The present teachings provide a method of performing a polymerase chain reaction (PCR) comprising; providing a crude sample comprising: deoxyribonucleic acid; optionally incubating the crude sample with NaOH at 5 mM to 25mM; mixing the crude sample with a direct buffer to form a nucleic acid containing solution; and performing a PCR on the deoxyribonucleic acid, wherein the direct buffer comprises at least 3%-8% glycerol, 0.2%-0.9% non-ionic surfactants, and 1000-3000 ug/ml BSA. Suitable non-ionic surfactants include, but not limited to, polysorbate (Tween), Tween 20, Triton-X 100 and the like.

**[0005]** The present teachings provide methods of performing a polymerase chain reaction (PCR) comprising; providing a crude sample comprising: deoxyribonucleic acid; optionally incubating the crude sample with NaOH at 5 mM to 25 mM; mixing the crude sample with a direct buffer to form a nucleic acid containing solution; and performing PCR on the solution, wherein the direct buffer comprises at least 5 PCR primer pairs, 10-50 mM Tris-HCl (pH 8.3), 30-80 mM KCl, 1.4-2.4 mM MgCl<sub>2</sub>, 0.01%-0.04% Sodium azide, 3%-8% glycerol, 100-350 uM of each dNTPs, 0.2%-0.9% polysorbate, 1000-3000 ug/ml BSA, and 0.10-0.35 U/ul of DNA polymerase.

**[0006]** In some embodiments, the present teachings provide methods of determining the identity of a human comprising; providing a crude sample comprising deoxyribonucleic acid from the human; optionally incubating the crude sample with NaOH at 5 mM to 25 mM; mixing the crude sample with the direct buffer forming a nucleic acid containing solution; wherein the direct buffer comprises a plurality of primer pairs; wherein each primer pair flanks a genomic locus containing a short tandem repeat (STR); performing PCR on the solution to form a plurality of PCR amplicons; wherein each PCR amplicon has an ascertainable size; and identifying the human by reference to size of the PCR amplicons; wherein the direct buffer further comprises 10-50 mM Tris-HCl (pH 8.3), 30-80 mM KCl, 1.4-2.4 mM MgCl<sub>2</sub>, 0.01%-0.04% Sodium azide, 3%-8% glycerol, 100-

350 uM of each dNTPs, 0.2%-0.9% polysorbate, 1000-3000 ug/ml BSA; and 0.101-0.35 U/ul of DNA polymerase.

**[0007]** In some of the embodiments include methods of preparing nucleic acids  
5 for a downstream enzymatic manipulation comprising; providing a crude sample comprising: deoxyribonucleic acid; optionally incubating the crude sample with NaOH at 5 mM to 25 mM; mixing the crude sample with a direct buffer to form a nucleic acid containing solution; and performing a downstream enzymatic ma-  
10 nipulation on the solution, wherein the direct buffer comprises 10-50 mM Tris-HCl (pH 8.3), 30-80 mM KCl, 1.4-2.4 mM MgCl<sub>2</sub>, 0.01%-0.04% Sodium azide, 3%-8% glycerol, 100-350 uM of each dNTPs, 0.2%-0.9% polysorbate, 1000-3000 ug/ml BSA, and 0.10-0.35U/ul of DNA polymerase. In some embodiments, the downstream enzymatic manipulation is PCR.

15 **[0008]** The present teachings also provide kits for genetic analysis, the kits comprising; a plurality of primer pairs, wherein each primer pair flanks a genomic locus containing a short tandem repeat (STR); and a direct buffer, wherein the direct buffer comprises 10-50 mM Tris-HCl (pH 8.3), 30-80 mM KCl, 1.4-2.4 mM MgCl<sub>2</sub>, 0.01%-0.04% sodium azide, 3%-8% glycerol, 100-350 uM of each  
20 dNTPs, 0.2%-0.9% polysorbate, 1000-3000 ug/ml BSA, and 0.10 -0.35U/ul of DNA polymerase. In some embodiments, the kits as set forth above can optionally include NaOH or other strong alkaline compounds, or other agents for cell lysis.

25 **[0009]** Other embodiments are reaction mixtures comprising; a direct buffer and a plurality of primer pairs, wherein each primer pair flanks a genomic locus containing a short tandem repeat (STR), and wherein the direct buffer comprises 10-50 mM Tris-HCl (pH 8.3), 30-80 mM KCl, 1.4-2.4 mM MgCl<sub>2</sub>, 0.01%-0.04% Sodium azide, 3%-8% glycerol, 100-350 uM of each dNTPs, 0.2%-0.9% poly-  
30 sorbate, 1200-3000 ug/ml BSA, and 0.10 - 0.35 U/ul of DNA polymerase. In some embodiments, the kits as set forth above can optionally include NaOH or other strong alkaline compounds, or other agents for cell lysis.

### Brief Description of the Figures

**[0010]** The skilled artisan will understand that the drawings described below are for illustration purposes only.

5

Figure 1 is an electropherogram of an STR profile of genomic DNA from a blood sample.

Figures 2A-2D are electropherograms of failed STR profiles of four blood samples spotted onto FTA paper.

Figures 3A through 12B are comparative electropherograms of STR profiles from 10 individuals whose blood was spotted onto FTA paper, a punch of which was placed into the direct buffer of the present teachings herein and designated by "A". While the electropherograms designated by "B" represent STR profiles of the same 10 individuals' blood prepared using the PowerPlex 16 HS purification system sold by Promega.

15

### Description of Exemplary Embodiments

**[0011]** In this application, the use of the singular includes the plural unless specifically stated otherwise. In this application, the word "a" or "an" means "at least one" unless specifically stated otherwise. In this application, the use of "or" means "and/or" unless stated otherwise. Furthermore, the use of the term "including," as well as other forms, such as "includes" and "included," is not limiting.

25

**[0012]** The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described.

### Some Definitions

30

**[0013]** As used herein, the term "crude sample" refers to a specimen of biologi-

cal origin suspected of containing nucleic acids, which has not undergone procedures for the isolation or purification of those nucleic acids. For example, a sample of blood is a crude sample. The cells in crude sample can optionally be lysed. Further, a sample of blood spotted on paper containing a lysis reagent, such as FTA paper (commercially available from Whatman), is a crude sample. A buccal swab of cheek cells is another example of a crude sample. Crude samples include, but are not limited to, blood, diluted blood, blood on paper, buccal swabs, and buccal swabs on a substrate for samples storage, such as FTA paper. One of skill in the art will recognize an enormous variety of other crude samples whose analysis would be facilitated by the present teachings.

**[0014]** As used herein, the term "direct buffer" refers to a buffer into which a crude sample can be placed. The direct buffer contains primers and enzyme for performing a downstream enzymatic manipulation, such as a polymerase chain reaction (PCR). The direct buffer allows for the liberation of the nucleic acids and for their amplification directly in the direct buffer, without the need for any nucleic acid isolation or purification. Illustrative cycling times and temperatures for PCR can be found in Sambrook et al., *Molecular Cloning*, 3rd Edition 1993. While the present teachings focus on the use of the direct buffer for PCR, it will be appreciated that one of skill in the art can easily employ the direct buffer of the present teachings as a front-end procedure for other types of downstream enzymatic manipulations, for example reverse transcription using a reverse transcriptase, or an oligonucleotide ligation assay using a ligase.

**[0015]** As used herein, "downstream" when used in reference to methods and manipulations performed on a target nucleic acids refers to methods and manipulations performed on a target nucleic acid sample subsequent to a method for liberating a nucleic acid from a biological sample, including, but not limited to, lysis of a cell to release the nucleic acid from the cell.

**[0016]** As used herein, "downstream enzymatic manipulation" refers to procedures performed on a nucleic acid sample, including, but not limited to PCR

using a polymerase, reverse transcription using a reverse transcriptase, or an oligonucleotide ligation assay using a ligase.

**[0017]** The term "strong alkaline compound" as used herein includes, but is not limited to, NaOH. Strong alkaline compounds can be used to lyse cells prior to the addition of some embodiments of direct buffer.

**[0018]** As used herein, the term "genomic DNA" refers to the chromosomal DNA sequence of a gene or segment of a gene, including the DNA sequences of non-coding as well as coding regions. Genomic DNA also refers to DNA isolated directly from cells or chromosomes or the cloned copies of all or part of such DNA.

**[0019]** The term "allele" as used herein refers to a genetic variation associated with a gene or a segment of DNA, i.e., one of two or more alternate forms of a DNA sequence occupying the same locus.

**[0020]** The term "locus" as used herein refers to a specific position on a chromosome or a nucleic acid molecule. Alleles of a locus are located at identical sites on homologous chromosomes.

**[0021]** As used herein, the term "short tandem repeat (STR) locus" refers to any region of the human genome which contains short, repetitive sequence elements of 3 to 7 base pairs in length.

**[0022]** As used herein, the term "genomic locus containing a short tandem repeat (STR)" refers to an STR locus in which the number of repetitive sequence elements (and net length of sequence) in a particular region of genomic DNA varies from allele to allele, and from individual to individual.

**[0023]** As used herein, the term "amplification primer" and "primer" refers to an oligonucleotide, which is capable of site-specifically annealing to an RNA or DNA region adjacent a target sequence, and serving as an initiation primer for

DNA synthesis under suitable conditions in which synthesis of a primer extension product is induced, e.g., in the presence of nucleotides and a polymerization-inducing agent such as a DNA-dependent DNA polymerase and at suitable temperature, pH, metal concentration, and salt concentration. Typically, a PCR reaction employs a pair of amplification primers also known as "primer pairs" including an "upstream" or "forward" primer and a "downstream" or "reverse" primer, which delimit a region of the RNA or DNA to be amplified.

**[0024]** As used herein, the term "amplifying" refers to a process whereby a portion of a nucleic acid is replicated using, for example, any of a broad range of primer extension reactions. Exemplary primer extension reactions include, but are not limited to, PCR. Unless specifically stated, "amplifying" refers to a single replication or to an arithmetic, logarithmic, or exponential amplification.

**[0025]** The terms "amplicon" and "PCR amplicon" as used herein refers to a broad range of techniques for increasing polynucleotide sequences, either linearly or exponentially and can be the product of an amplification reaction. An amplicon can be double-stranded or single-stranded, and can include the separated component strands obtained by denaturing a double-stranded amplification product. In certain embodiments, the amplicon of one amplification cycle can serve as a template in a subsequent amplification cycle. Exemplary amplification techniques include, but are not limited to, PCR or any other method employing a primer extension step. Other non-limiting examples of amplification include, but are not limited to, ligase detection reaction (LDR) and ligase chain reaction (LCR). Amplification methods can comprise thermal-cycling or can be performed isothermally. In various embodiments, the term "amplification product" includes products from any number of cycles of amplification reactions.

**[0026]** The term "nucleic acid sequence" as used herein can refer to the nucleic acid material itself and is not restricted to the sequence information (i.e. the succession of letters chosen among the five base letters A, C, G, T, or U) that biochemically characterizes a specific nucleic acid, for example, a DNA or RNA molecule.

**[0027]** As used herein, the terms "polynucleotide", "nucleic acid", or "oligonucleotide" refers to a linear polymer of natural or modified monomers or linkages, including deoxyribonucleic acid, deoxyribonucleosides, ribonucleosides, polyamide nucleic acids, and the like, joined by inter-nucleosidic linkages and have the capability of specifically binding to a target polynucleotide by way of a regular pattern of monomer-to-monomer interactions, such as Watson-Crick type of base pairing, and capable of being ligated to another oligonucleotide in a template-driven reaction. Usually monomers are linked by phosphodiester bonds or analogs thereof to form oligonucleotides ranging in size from a few monomeric units, e.g. 3-4, to several hundreds of monomeric units. Whenever a polynucleotide such as an oligonucleotide is represented by a sequence of letters, such as "ATGCCTG," it will be understood that the nucleotides are in 5'→ 3' order from left to right and that "A" denotes deoxyadenosine, "C" denotes deoxycytidine, "G" denotes deoxyguanosine, and "T" denotes deoxythymidine, unless otherwise noted. The letters A, C, G, and T can be used to refer to the bases themselves, to nucleosides, or to nucleotides comprising the bases, as is standard in the art. In naturally occurring polynucleotides, the inter-nucleoside linkage is typically a phosphodiester bond, and the subunits are referred to as "nucleotides."

20

**[0028]** As used herein "sequence determination", "determining a nucleotide base sequence", "sequencing", identifying and like terms includes determination of partial as well as full sequence information. That is, the term includes sequence comparisons, fingerprinting, and like levels of information about a target polynucleotide, as well as the express identification and ordering of each nucleoside of the target polynucleotide within a region of interest. In certain embodiments, "sequence determination" comprises identifying a single nucleotide, while in other embodiments more than one nucleotide is identified. Identification of nucleosides, nucleotides, and/or bases are considered equivalent herein. It is noted that performing sequence determination on a polynucleotide typically yields equivalent information regarding the sequence of a perfectly complementary polynucleotide and thus is equivalent to sequence determination performed directly on a perfectly complementary polynucleotide.

30

**[0029]** As used herein, "plurality" in reference to oligonucleotide probes includes sets of two or more oligonucleotide probes where there may be a single "common" oligonucleotide probe that is usually specific for a non-variable region of a target polynucleotide and one or more "wild-type" and/or "mutant" oligonucleotide probes that are usually specific for a region of a target polynucleotide that contains allelic or mutational variants in sequence.

**[0030]** As used herein, "Nucleic acid polymerase" or "polymerase" refers to any polypeptide that catalyzes the synthesis of a polynucleotide using an existing polynucleotide as a template.

**[0031]** As used herein, "DNA polymerase" refers to a nucleic acid polymerase that catalyzes the synthesis of DNA using an existing polynucleotide as a template.

## 15 **Detailed Description**

**[0032]** A large number of experiments were performed, varying the respective concentration of each of the ingredients of a desired direct buffer, including Tris-HCl, KCl, dNTPs, BSA, AmpliTaq Gold DNA polymerase, MgCl<sub>2</sub>, and single stranded binding protein (SSB), glycerol, and non-ionic surfactant. These experiments used, for example, humic acid as a representative for the inhibitors typically present in difficult to analyze samples of biological material, and hence served as an easy to produce proxy for crude samples. The results of these experiments indicated that the following formulations were particularly effective in producing high quality results when the samples were analyzed to identify STR alleles.

**[0033]** The present teachings include direct buffers comprising 3%-8% glycerol, 0.2%-0.9% non-ionic surfactants, and 1200-3000 ug/ml BSA.

30

**[0034]** The present teachings include a direct buffers comprising 10-50 mM Tris-HCl (pH 8.3), 30-80 mM KCl, 1.4-2.4 mM MgCl<sub>2</sub>, 0.01%-0.04% Sodium azi-

de, 3%-8% glycerol, 100-350  $\mu$ M of each dNTPs, 0.2%-0.9% non-ionic surfactants, 1200-3000  $\mu$ g/ml BSA, and 0.10l-0.35U/ $\mu$ l of DNA polymerase.

**[0035]** In some embodiments, the non-ionic surfactants can be polysorbate  
5 (Tween, Tween 20), Triton-X 100 and the like.

**[0036]** The reagents used in the direct buffer are readily available from commercial suppliers. For example, DNA polymerase is commercially available from Applied Biosystems. Suitable DNA polymerases include Pol A, Pol B, Pol C, Pol  
10 D, Pol X, and Pol Y DNA polymerases and a Type I, Type II and Type III DNA polymerase. Generally, thermostable DNA polymerases such as Taq, Pfu, Vent™DeepVent™, 9° North™, are used in PCR. The DNA polymerases may be modified so as to be inactive prior to subsequent treatment, e.g. heat; for example see US patent 5,773,258 (chemically modified DNA polymerases), US  
15 patent 5,338,671 antibody bound DNA polymerases. DNA polymerases are known to those skilled in the art. DNA polymerases include DNA-dependent polymerases, which use DNA as a template, or RNA-dependent polymerases, such as reverse transcriptase, which use RNA as a template.

**[0037]** Based on sequence homology, bacterial DNA polymerases can be subdivided into seven different families: A, B, C, D, X, Y, and RT. DNA-dependent DNA polymerases fall into one of six families (A, B, C, D, X, and Y), with most falling into one of three families (A, B, and C). See, e.g., Ito et al. (1991) Nucleic  
20 Acids Res. 19:4045-4057; Braithwaite et al. (1993) Nucleic Acids Res. 21:787-802; Filee et al. (2002) J. Mol. Evol. 54:763-773; and Alba (2001) Genome Biol. 2:3002.1-3002.4. Certain DNA polymerases may be single-chain polypeptides (e.g., certain family A and B polymerases) or multi-subunit enzymes (e.g., certain family C polymerases) with one of the subunits having polymerase activity.  
*Id.* A fusion protein may comprise a DNA polymerase selected from a family A,  
25 B, C, D, X, or Y polymerase.  
30

**[0038]** Family A polymerases ("Pol A") include both replicative and repair polymerases. Replicative members from this family include T7 DNA polymerase and

the eukaryotic mitochondrial DNA Polymerase  $\gamma$ . Among the repair polymerases are *E. coli* DNA Pol I, *Thermus aquaticus* Pol I (Taq DNA polymerase), and *Bacillus stearothermophilus* Pol I. Excision repair and processing of Okazaki fragments generated during lagging strand synthesis are performed by the repair polymerases. Because most thermostable Pol A enzymes do not possess the 3' to 5' exonuclease activity, they are incapable of proofreading the newly synthesized nucleic acid strand and consequently have high error rates.

**[0039]** Family B polymerases ("Pol B") are substantially replicative polymerases including the major eukaryotic DNA polymerases  $\alpha$ ,  $\delta$ ,  $\epsilon$ , and also DNA polymerase  $\zeta$ . Pol B polymerases also include DNA polymerases encoded by some bacteria and bacteriophages, of which the best characterized are from T4, Phi29 and RB69 bacteriophages. Pol B enzymes are involved in both leading and lagging strand synthesis and are noteworthy for their remarkable accuracy during replication as many have strong 3'-5' exonuclease activity the exceptions being DNA polymerase  $\alpha$  and  $\zeta$  which lack proofreading activity.

**[0040]** BSA is commercially available from a variety of sources, for example catalog number 10711454001 from Roche. FTA paper is commercially available from Whatman. In some embodiments, FTA paper is used herein with bloodstains. For example, Bloodstain Card from Whatman (Cat# WB 10 0014).

**[0041]** In some embodiments, the FTA paper containing blood or buccal cells is cut out to remove a small region containing biological material, e.g., a circular punch of 0.5mm to 1.2mm in diameter, or 1.0-1.5mm in diameter, or 1.5-2.0mm in diameter.

**[0042]** In some embodiments, the paper is placed directly into the PCR mix comprising the direct buffer for PCR reaction. In some embodiments, a wash of the FTA paper is not required before placing the FTA paper in the direct buffer.

**[0043]** In some embodiments, when the cells are not initially lysed, e.g., when non-FTA paper is used, a NaOH solution at 5-25 mM is incubated with non-FTA

before mixing with the direct buffer and performing a PCR reaction. In other embodiments, the cells may be lysed by exposure to reagents other than NaOH.

5 **[0044]** In some embodiments, the direct buffer further comprises a plurality of PCR primer pairs. For example, in some embodiments, the direct buffer comprises 5 primer pairs. In some embodiments, the direct buffer comprises 10 primer pairs. In some embodiments, the direct buffer comprises greater than 10 primer pairs. In some embodiments, the direct buffer does not comprise PCR primer  
10 pairs, but rather the PCR primer pairs are added at a separate time.

**[0045]** Some embodiments of the subject methods eliminate the need for a sample purification procedure prior to performing PCR. The same protocol can be applied to both blood and buccal cell samples on FTA cards. In addition, the  
15 physical sample handling is significantly reduced, therefore this can prevent possible cross-contamination between samples as well as eliminate the possibility of human errors. In some embodiments the amount of time required from FTA card to STR profiles can be reduced by at least 1 1/2 hours. The method is compatible with the current automation instruments available in the forensic  
20 market. The costs associated with the purification of DNA from FTA can be eliminated. The success rate of getting a full STR profile is comparable when compared to the traditional standard sample preparation method.

**[0046]** As shown in Figure 1, a sample of genomic DNA used directly with the  
25 Applied Biosystems Identifier HID v.1 Kit provides a full STR profile. However, the STR profile is either partial or undetectable when blood from genomic DNA is taken from blood spotted on an FTA disc punch (1.2 mm punch) without washing the disc to remove materials which interfere with subsequent sample testing, e.g., STR profiling via direct PCR, see Figures 2A-2D.

30

**[0047]** Further comparative data between the claimed invention and a commercially available product from another reveals in all cases that the direct buffer of the claimed invention provides a full STR profile by direct PCR in 10 out of 10

blood samples spotted on FTA paper using a 1.2 mm size punch (specifically, Figures 3-12, electropherograms labeled "A"). Full STR profiles were seen with another's STR kit in only four out of 10 samples tested (Figures 3B, 4B, 7B and 8B), partial STR profiles in five of the 10 samples tested (Figures 5B-7B and 9B-10B) and no STR profile in one sample (Figure 6B).

### Examples

[0048] In a first example, blood was applied to FTA paper (Whatman) and air-dried. A 0.5 mm disc punch from the FTA paper was made and placed into the direct buffer containing PCR primers from the commercially available Identifier® Human Identity Kit (Applied Biosystems). PCR was then performed.

[0049] In a second example, 100-fold dilutions of blood were made with TE buffer (10mM Tris-Cl and 0.1 mM EDTA at pH 8.0). 1 ul of diluted blood was used to set up a PCR in the direct buffer.

[0050] In a third example, buccal swab samples were collected and placed in 500ul TE buffer. The resulting suspension was heated at 97°C for 5 minutes. 10 ul of the resulting suspension was used to set up a PCR in the direct buffer.

### 20 Exemplary Kits in Accordance with Some Embodiments of the Present Teachings

[0051] The present teachings also provide kits designed to expedite performing certain methods. In some embodiments, kits serve to expedite the performance of the methods of interest by assembling two or more components used in carrying out the methods. In some embodiments, kits may contain components in pre-measured unit amounts to minimize the need for measurements by end-users. In some embodiments, kits may include instructions for performing one or more methods of the present teachings. In certain embodiments, the kit components are optimized to operate in conjunction with one another.

**[0052]** While the present teachings have been described in terms of these exemplary embodiments and experimental data, the skilled artisan will readily understand that numerous variations and modifications of these exemplary embodiments are possible without undue experimentation.

5

**[0053]** Thus, in some embodiments, the present teachings provide a kit comprising; a plurality of primer pairs, wherein each primer pair flanks a genomic locus containing a short tandem repeat (STR); and a direct buffer, wherein the direct buffer comprises 10-50 mM Tris-HCl (pH 8.3), 30-80 mM KCl, 1.4-2.4 mM  
10 MgCl<sub>2</sub>, 0.01%-0.04% Sodium azide, 3%-8% glycerol, 100-350 uM of each dNTPs, 0.2%-0.9% non-ionic surfactants, 1200-3000 ug/ml BSA, and 0.10 -0.35 U/ul of AmpliTaq Gold DNA polymerase.

**[0054]** Such a kit can be used, for example, in the identification of an organism  
15 such as a human by the collection of polymorphic microsatellites analyzed, using for example capillary electrophoresis. Illustrative procedures for performing such human identification can be found for example in the Identifiler HID kit, commercially available from Applied Biosystems, as well as U.S. Patents 6,221,598, 6,479,235, 5,843,660, and 7,008,771. In some embodiments, the  
20 kits, methods and reaction mixtures provided by the present teachings can be used with procedures for multiplexed PCR of degraded samples, as found for example in WO05054515 to Dimsoski and Woo.

**[0055]** In some embodiments, the direct buffer in the kit comprises 0.2%-0.9%  
25 polysorbate, 3%-8% glycerol, 1200-3000 ug/ml BSA.

**[0056]** In some embodiments, the direct buffer in the kit further comprises 10-50 mM Tris-HCl (pH 8.3), 30-80 mM KCl, 1.4-2.4 mM MgCl<sub>2</sub>, 0.01%-0.04% Sodium azide, 3%-8% glycerol, 100-350 uM of each dNTPs, 0.2%-0.9% polysorbate,  
30 1200-3000 ug/ml BSA, and 0.10 -0.35U/ul of AmpliTaq Gold DNA polymerase.

**[0057]** In some embodiments, the direct buffer in the kit feature comprises

NaOH at 5 mM-25 mM. In some embodiments, the NaOH is supplied in a vial separate from the direct buffer.


**Patentkrav**

1. Fremgangsmåde omfattende:
  - 5 tilvejebringelse af blod på papir eller en bukkal prøvevatpind på papir, hvor papiret indeholder et lyseringsreagens, anbringelse af blodet på papir eller den bukkale prøvevatpind på papir i en direkte buffer til at danne en nucleinsyreholdig opløsning, og udføre en PCR på den nucleinsyreholdige opløsning, hvor den direkte buffer omfatter 0,2% - 0,9% polysorbat, 3% -8% glycerol og 1000 - 3000 µg/ml BSA.
- 15 2. Fremgangsmåde ifølge krav 1, hvor den direkte buffer yderligere omfatter 10 - 50 mM Tris-HCl (pH 8,3), 30 - 80 mM KCl, 1,4 - 2,4 mM MgCl<sub>2</sub>, 0,01% - 0,04% natriumazid, 100 - 350 µM af hver af dNTP og 0,10 - 0,35 U/µl DNA polymerase.
3. Fremgangsmåde ifølge krav 1, hvor polysorbatet er polysorbat 20.
- 20 4. Fremgangsmåde ifølge krav 1, hvor den direkte buffer yderligere omfatter en række primerpar.
- 25 5. Fremgangsmåde ifølge krav 4, hvor humant blod eller en human bukkal vatpindsprøve tilvejebringes, hvor hvert primerpar flankeres et genomisk locus indeholdende en kort tandemgentagelse, hvor PCR udføres på den nucleinsyreholdige opløsning til dannelse af en række PCR ampliconer, hvor hver PCR amplicon har en tilskrivelig størrelse, og fremgangsmåden yderligere omfatter identificering af mennesket med reference til størrelsen af PCR ampliconerne.
- 30 6. Reaktionsblanding omfattende en direkte buffer, blod på papir eller en bukkal vatpind på papir og en række primerpar, hvor papiret, der indeholder et lyseringsreagens, og hvor den direkte buffer omfatter 10 mM Tris-HCl (pH 8,3), 30 -


80 mM KCl, 1,4 - 2,4 mM MgCl<sub>2</sub>, 0,01% - 0,04% natriumazid, 3% - 8% glycerol, 100 - 350 µM af hver af dNTP, 0,2% - 0,9% polysorbat, 20, 1200 - 3000 µg/ml BSA og 0,10 - 0,35 U/µl DNA polymerase.

- 5 7. Fremgangsmåde ifølge krav 1, hvor papiret er FTA papir.
8. Blanding ifølge krav 6, hvor papiret er FTA papir.
9. Fremgangsmåde ifølge krav 1, hvor tilvejebringelse af blod på papir eller
- 10 en bukkalvatpind på papir omfatter tilvejebringelse på FTA papir og spotte blod eller indsamle bukkale celler på papiret.

Figure 1





Figures 2A and 2B



Figures 2C and 2D

C - Upper



D - Lower



Figures 3A and 3B

C - Upper



D - Lower



Figures 4A and 4B

C - Upper



D - Lower



Figures 5A and 5B

C - Upper


D - Lower



Figures 6A and 6B

C - Upper



D - Lower



Figures 7A and 7B

C - Upper



D - Lower



Figures 8A and 8B

C - Upper


D - Lower



Figures 9A and 9B

C - Upper



D - Lower



Figures 10A and 10B

C - Upper


D - Lower



Figures 11A and 11B

C - Upper

D - Lower



Figures 12A and 12B

C - Upper

D - Lower

